Authors
Latest:
IMvigor130 Shows Improvement in PFS with Atezolizumab in Metastatic Urothelial CarcinomaEnrique Grande, MD, discusses the characteristics of metastatic urothelial cancer, which rationalizes the use of atezolizumab in combination with platinum-based chemotherapy in the IMvigor130 trial, in patients with locally advanced or metastatic urothelial carcinoma.<br />
Latest:
Addressing the State of Community Oncology in Florida and the Role of FLASCOEric Harris, DO, hematologist/oncologist, Florida Cancer Specialists & Research Institute, gives Targeted Oncology an insiders perspective on the current state of community oncology in Florida and some ways the Florida Society of Clinical Oncology (FLASCO) aids in improving patient care by helping physicians.
Latest:
Using Cabozantinib and Vandetanib in Medullary Thyroid CancerEric J. Sherman, MD, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, comments on the use of cabozantinib and vandetinib in medullary thyroid cancer.
Latest:
COSMIC-313 and Advice to Community Oncologists Treating Advanced RCCDr Eric Jonasch reviews key efficacy outcomes from the COSMIC 313 trial, its clinical implications, and shares advice for community oncologists treating patients with advanced renal cell carcinoma.
Latest:
Dr. Eric Lim on the Diagnosis of Lung Cancer in Non-Smoker PatientsEric Lim, MD, consultant thoracic surgeon, Royal Brompton Hospital, Senior lecturer in thoracic surgery and reader, Imperial College London, discusses the decline in smoking not correlating to the current amount of lung cancer diagnoses.
Latest:
Prognostic Factors to Watch Out for in Patients With Ovarian CancerEric Pujade-Lauraine, MD, PhD, discusses the prognostic factors researchers are looking for when testing patients with ovarian cancer.
Latest:
Armored CAR T Cells in Multiple MyelomaEric Smith, MD, PhD, discusses the use of armored chimeric antigen receptor T cells in multiple myeloma.
Latest:
Dr. Van Cutsem Discusses Regorafenib for the Treatment of Patients With Chemorefractory mCRCEric Van Cutsem, MD, PhD, discusses regorafenib for the treatment of patients with chemorefractory metastatic colorectal cancer (mCRC).
Latest:
Dr. Eric P. Winer on Pathologic Complete Response and Disease Free Survival in Breast CancerWiner says patients who do well on carboplatin and show both a good pathologic complete response and good disease free survival may be patients who have refractory disease and are responding well to the treatment, while others may be patients who were bound to do well regardless.
Latest:
The Status of Biomarker Research in Low-Grade GliomasErica Bell, PhD, assistant professor, radiation oncology, Ohio State University Comprehensive Cancer Center, discusses the status of biomarker research in low-grade gliomas.
Latest:
Closing Thoughts on Data Updates From ESMO 2023Following their review of data presented at ESMO 2023, the Oncology Brothers offer their key takeaways on the evolving breast cancer treatment landscape.
Latest:
Identification of Certain Tumor Characteristics Enhances Immunotherapy Response in NSCLCAdvances in the development of targeted therapies and the identification of emerging biomarkers of response to treatment have led to an improved ability to predict and enhance responses to immunotherapeutic agents in non–small cell lung cancer.
Latest:
Understanding Virus-Induced Cancers Can Elucidate Precancerous Lesion DevelopmentApproximately 20% of cancers worldwide are linked to an infectious agent. Currently, there are seven known oncogenic viruses, which include Epstein-Barr virus, hepatitis virus B and C, human papillomavirus, human T cell lymphoma virus 1, Kaposi sarcoma virus and Merkel cell polyomavirus. Among these agents, HBV, HCV and HPV each contribute to ap- proximately 5% of all cancer cases.
Latest:
Melanoma Brain Metastases: Q&A With Keith Black, MDMalignant melanoma is one of the most common primary tumors to spread to the brain.
Latest:
Actionable Mutations Impacting Breast Cancer TreatmentErin Wysong Hofstatter, MD, associate professor at Yale Cancer Center and co-director of the Cancer Genetics and Prevention Program, discusses the actionable mutations that impact treatment and surgical decisions in breast cancer.
Latest:
ACCC Recognizes Ethan Basch on Symptom Monitoring in OncologyEthan Basch, MD, MSc, recently received the Clinical Research Award from the Association of Community Cancer Centers during the 2019 National Oncology Conference. Basch explains the importance of receiving this award in light of his work around patient-reported outcomes for symptom monitoring in oncology.
Latest:
Delivering Optimal Outcomes in Prostate Cancer Despite Adverse EventsEugene B. Cone, MD, discusses the strategies for treating patients with prostate cancer who develop adverse events, such as cardiac events and immune-related events.
Latest:
FLT3 Mutated AML: Are Triplets Better Than Doublets?FLT3 tyrosine kinase inhibitor combination regimens may hold promise to not only improve outcomes for older individuals with FLT3-mutant but potentially for all patients , regardless of age or fitness.
Latest:
Roundtable Discussion: Yu Explores the Role of Hereditary Germline Testing in Nonmetastatic CRPCDuring a Targeted Oncology Case-Based Roundtable event, Evan Y. Yu, MD leads a discussion on hereditary germline mutations impact on prostate-cancer risk.
Latest:
Optimizing Clinical Trial Design in Brain Cancer, Other Cancer TypesEvanthia Galanis, MD, professor of oncology, Mayo Clinic, discusses how to best optimize clinical trial design in brain cancer and other cancer types.
Latest:
Dr. Vokes Discusses PARP Inhibitors in Lung CancerEverett E. Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medicine, and biological sciences chair, department of medicine, discusses PARP inhibitors for the treatment of lung cancer.
Latest:
An Overview of Head and Neck Cancer Treatment StrategiesEverett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses current treatment strategies in head and neck cancer.
Latest:
Evolving Treatment Landscape in Lower-Risk MDSIn the third article of this series, Eytan M. Stein, MD, discusses the treatment landscape for patients with lower-risk MDS and reviews follow-up data from the IMerge clinical trial.
Latest:
Unmet Needs and the Future of AML TreatmentEytan Stein, MD and Hetty Carraway, MD, wrap up their discussion with a review of the unmet needs in AML treatment and exciting therapies in the pipeline.
Latest:
The Introduction of Immunotherapy to the Treatment of Head and Neck CancersEzra Cohen, MD, discusses the advancing field of immunotherapy in the treatment landscape for patients with head and neck cancers. Prior to the use of PD-1/PD-L1 blockades, which have been the most tested immunotherapy in this setting, there were little treatment options.
Latest:
Steps to Successful Management of Immunotherapy ToxicitiesEzra Cohen, MD, FRCPSC, FASCO, discusses the most important parts of successfully managing toxicities related to treatment with immunotherapy.
Latest:
Different Therapeutic Options Required for Subtypes in Mantle Cell LymphomaEzzat Elhassadi, MD, a consultant hematologist at the University Hospital Waterford in Ireland, discusses the therapeutic approach for different subtypes of mantle cell lymphoma. MCL is a spectrum of diseases that should be treated differently, he says.
Latest:
Using Platinum Agents in Different Settings of TNBCFabrice André, MD, PhD, professor in the Department of Medical Oncology at the Institut Gustave Roussy in Villejuif, France, addresses questions regarding the use of platinum regimens for patients with triple-negative breast cancer (TNBC). He discusses 2 platinum agents, cisplatin and carboplatin, and when it is recommended that these agents be used.
